TWi Biotechnology, Inc. (TPEX:6610)
Taiwan · Delayed Price · Currency is TWD 44.60
-1.85 (-3.98%)
Sep 30, 2026, 1:58 PM CST
TWi Biotechnology Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
27
Market Cap
9.55B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 66.40M | 65.15M | 5,228.81% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Adimmune | 1.37B |
| PharmaEngine | 1.03B |
| TCM Biotech International | 701.63M |
| Tanvex BioPharma | 657.56M |
| Polaris Group | 67.95M |
| Lumosa Therapeutics | 34.37M |
| AP Biosciences | 32.25M |
| Locus Cell | 19.40M |